Atopic Dermatitis
📧 Sign up to get email alerts when something new happens for Atopic Dermatitis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
This clinical trial update indicates ongoing recruitment for a University of Pittsburgh study collecting blood, urine, and tissue samples fr…
-
CLINICAL_TRIALS research · 2025-12-29Clinical Trial Update: Staphylococcal Toxins in Atopic Dermatitis and Eczema Herpeticum [NA]
The update covers a completed clinical trial examining the role of staphylococcal toxins in atopic dermatitis and eczema herpeticum. Sponsor…
-
CLINICAL_TRIALS trial_result · 2025-12-29Clinical Trial Update: Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)
This update provides the current status of a Dupixent (dupilumab) trial for atopic dermatitis, noting that the study is active but not recru…
-
CLINICAL_TRIALS research · 2025-12-26Clinical Trial Update: URGO FilmoCream Eczema + Dermocorticoids in Atopic Dermatitis [NA]
Clinical trial update indicating URGO FilmoCream Eczema + Dermocorticoids for Atopic Dermatitis is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2025-12-24Clinical Trial Update: Efficacy and Safety of Revodiol Calming Cream® in Atopic Dermatitis. [NA]
This clinical trial update reports the efficacy and safety results of Revodiol Calming Cream for atopic dermatitis in a completed study.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-12-23Clinical Trial Update: Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED) [Phase 3]
A Phase 3 trial evaluating roflumilast, a PDE4 inhibitor, for the management of atopic dermatitis (eczema) has completed and results have be…
-
CLINICAL_TRIALS trial_result · 2025-12-23Clinical Trial Update: A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants [Phase 1]
Phase 1 study assessing the bioavailability of Rocatinlimab (AMG 451) when administered via vial versus prefilled syringe in healthy partici…
-
CLINICAL_TRIALS trial_result · 2025-12-23Clinical Trial Update: Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis [Phase 3]
An open-label Phase 3 extension trial evaluating roflumilast, a PDE-4 inhibitor, for the management of atopic dermatitis; the trial has comp…
-
CLINICAL_TRIALS trial_result · 2025-12-23Clinical Trial Update: Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis [EARLY_Phase 1]
An early-phase study evaluating whether Rocatinlimab (AMG 451) alters the pharmacokinetics of multiple cytochrome P450 substrates in adults …
-
CLINICAL_TRIALS research · 2025-12-23Clinical Trial Update: Frequency of Palpebral Involvement in Adult With Atopic Dermatitis
A clinical trial is investigating how often the palpebral (eyelid) area is involved in adults with atopic dermatitis; the study is currently…
-
CLINICAL_TRIALS trial_result · 2025-12-22Clinical Trial Update: A Study of Orally Administered IPG7236 in Healthy Adult Participants [Phase 1]
Phase 1 study of oral IPG7236 in healthy adults for atopic dermatitis has been terminated.
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis [Phase 2]
Novartis is conducting a Phase 2 platform study to evaluate investigational compounds for moderate to severe atopic dermatitis, and the tria…
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: Topical Treatment for Atopic Dermatitis [NA]
A topical treatment for atopic dermatitis is currently recruiting, according to a clinical trial record.
-
CLINICAL_TRIALS trial_result · 2025-12-19Clinical Trial Update: The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance. [Phase 4]
Phase 4 trial evaluating the effects of ruxolitinib cream in adults with atopic dermatitis and sleep disturbance; the study was terminated w…
-
CLINICAL_TRIALS research · 2025-12-19Clinical Trial Update: A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis [Phase 1]
A Phase 1/1b clinical trial is evaluating the safety, tolerability and pharmacokinetics of ZL-1503 in healthy volunteers and adults with mod…
-
CLINICAL_TRIALS research · 2025-12-19Clinical Trial Update: Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis [Phase 1]
Phase 1 clinical trial update describing safety and pharmacokinetics evaluation of LPX-TI641 in adults with atopic dermatitis and psoriasis.…
-
CLINICAL_TRIALS trial_result · 2025-12-18Clinical Trial Update: Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis [Phase 2]
A Phase 2 trial evaluating Topical YR001 Ointment in adults with mild to moderate atopic dermatitis has completed.
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis [Phase 3]
A Phase 3 clinical trial is evaluating the efficacy and safety of ruxolitinib cream in children and adolescents aged 6 to <18 with moderate …
-
FDA approval · 2025-12-17FDA Approved: ADBRY — Supplemental Application (LEO Pharma Inc.)
The FDA approved a supplemental application for ADBRY (tralokinumab-ldrm) submitted by LEO Pharma Inc.
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis [Phase 3]
Phase 3 clinical trial update assessing the long-term safety and efficacy of Lebrikizumab (LY3650150) in participants aged 6 months to under…
-
FDA approval · 2025-12-16FDA Approved: BECLOMETHASONE DIPROPIONATE — Original Application (Amneal Pharmaceuticals NY LLC)
The FDA approved Amneal Pharmaceuticals NY LLC's Beclomethasone Dipropionate as an original-application generic medication, a topical cortic…
-
CLINICAL_TRIALS research · 2025-12-16Clinical Trial Update: Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating drug candidate 611 for moderate-to-severe atopic dermatitis in Chinese children and adolescents is cur…
-
CLINICAL_TRIALS trial_result · 2025-12-15Clinical Trial Update: An Evaluation of 9MW1911 Injection in Healthy Subjects [Phase 1]
Phase 1 evaluation of 9MW1911 Injection in healthy subjects has been completed, assessing safety in potential indications including asthma, …
-
CLINICAL_TRIALS trial_result · 2025-12-15Clinical Trial Update: Baricitinib Versus Azathioprine in Patients With Moderate-to-Severe Atopic Dermatitis [NA]
A completed clinical trial compared baricitinib to azathioprine in patients with moderate-to-severe atopic dermatitis.
-
FDA label_change · 2025-12-12FDA Approved: ADBRY — Supplemental Application (LEO Pharma Inc.)
The FDA approved a supplemental application for Adbry (tralokinumab-ldrm) from LEO Pharma Inc.